Individual variations in motives for nicotine self-administration in male rats: evidence in support for a precision psychopharmacology.
Journal
Translational psychiatry
ISSN: 2158-3188
Titre abrégé: Transl Psychiatry
Pays: United States
ID NLM: 101562664
Informations de publication
Date de publication:
09 Feb 2024
09 Feb 2024
Historique:
received:
30
11
2023
accepted:
10
01
2024
revised:
07
01
2024
medline:
10
2
2024
pubmed:
10
2
2024
entrez:
9
2
2024
Statut:
epublish
Résumé
The significant heterogeneity in smoking behavior among smokers, coupled with the inconsistent efficacy of approved smoking cessation therapies, supports the presence of individual variations in the mechanisms underlying smoking. This emphasizes the need to shift from standardized to personalized smoking cessation therapies. However, informed precision medicine demands precision fundamental research. Tobacco smoking is influenced and sustained by diverse psychopharmacological interactions between nicotine and environmental stimuli. In the classical experimental rodent model for studying tobacco dependence, namely intravenous self-administration of nicotine, seeking behavior is reinforced by the combined delivery of nicotine and a discrete cue (nicotine+cue). Whether self-administration behavior is driven by the same psychopharmacological mechanisms across individual rats remains unknown and unexplored. To address this, we employed behavioral pharmacology and unbiased cluster analysis to investigate individual differences in the mechanisms supporting classical intravenous nicotine self-administration (0.04 mg/kg/infusion) in male outbred Sprague-Dawley rats. Our analysis identified two clusters: one subset of rats sought nicotine primarily for its reinforcing effects, while the second subset sought nicotine to enhance the reinforcing effects of the discrete cue. Varenicline (1 mg/kg i.p.) reduced seeking behavior in the former group, whereas it tended to increase in the latter group. Crucially, despite this fundamental qualitative difference revealed by behavioral manipulation, the two clusters exhibited quantitatively identical nicotine+cue self-administration behavior. The traditional application of rodent models to study the reinforcing and addictive effects of nicotine may mask individual variability in the underlying motivational mechanisms. Accounting for this variability could significantly enhance the predictive validity of translational research.
Identifiants
pubmed: 38336930
doi: 10.1038/s41398-024-02774-6
pii: 10.1038/s41398-024-02774-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
85Subventions
Organisme : Agence Nationale de la Recherche (French National Research Agency)
ID : ANR-10-LABX-43
Informations de copyright
© 2024. The Author(s).
Références
Benowitz NL. Cigarette smoking and nicotine addiction. Med Clin North Am. 1992;76:415–37.
pubmed: 1548969
doi: 10.1016/S0025-7125(16)30360-1
Caggiula AR, Donny EC, White AR, Chaudhri N, Booth S, Gharib MA, et al. Cue dependency of nicotine self-administration and smoking. Pharmacol Biochem Behav. 2001;70:515–30.
pubmed: 11796151
doi: 10.1016/S0091-3057(01)00676-1
Caggiula A, Donny E, Chaudhri N, Perkins K, Evansmartin F, Sved A. Importance of nonpharmacological factors in nicotine self-administration. Physiol Behav. 2002;77:683–7.
pubmed: 12527019
doi: 10.1016/S0031-9384(02)00918-6
Chaudhri N, Caggiula AR, Donny EC, Palmatier MI, Liu X, Sved AF. Complex interactions between nicotine and nonpharmacological stimuli reveal multiple roles for nicotine in reinforcement. Psychopharmacology. 2006;184:353–66.
pubmed: 16240165
doi: 10.1007/s00213-005-0178-1
Garcia-Rivas V, Deroche-Gamonet V. Not all smokers appear to seek nicotine for the same reasons: implications for preclinical research in nicotine dependence. Addict Biol. 2019;24:317–34.
pubmed: 29480575
doi: 10.1111/adb.12607
Bani M, Andorn A, Heidbreder C. Pharmacologically, are smokers the same as non-smokers? Curr Opin Pharm. 2014;14:42–9.
doi: 10.1016/j.coph.2013.11.003
McClernon FJ, Froeliger B, Rose JE, Kozink RV, Addicott MA, Sweitzer MM, et al. The effects of nicotine and non-nicotine smoking factors on working memory and associated brain function. Addict Biol. 2016;21:954–61.
Shiffman S, Dunbar MS, Scholl SM, Tindle HA. Smoking motives of daily and non-daily smokers: a profile analysis. Drug Alcohol Depend. 2012;126:362–8.
pubmed: 22784601
pmcid: 3970262
doi: 10.1016/j.drugalcdep.2012.05.037
Shiffman S, Dunbar MS, Ferguson SG. Stimulus control in intermittent and daily smokers. Psychol Addict Behav. 2015;29:847–55.
pubmed: 25706335
pmcid: 4624616
doi: 10.1037/adb0000052
Stoker AK, Markou A. Neurobiological bases of cue- and nicotine-induced reinstatement of nicotine seeking: implications for the development of smoking cessation medications. Curr Top Behav Neurosci. 2015;24:125–54.
pubmed: 25638336
doi: 10.1007/978-3-319-13482-6_5
Caggiula AR, Donny EC, Palmatier MI, Liu X, Chaudhri N, Sved AF. The role of nicotine in smoking: a dual-reinforcement model. Nebr Symp Motiv. 2009;55:91–109.
pubmed: 19013940
pmcid: 2694565
doi: 10.1007/978-0-387-78748-0_6
Benowitz NL. Nicotine addiction. N Engl J Med. 2010;362:2295–303.
pubmed: 20554984
pmcid: 2928221
doi: 10.1056/NEJMra0809890
Garcia-Rivas V, Deroche-Gamonet V. Not all smokers appear to seek nicotine for the same reasons: implications for preclinical research in nicotine dependence. Addict Biol. 2018;24:317–34.
Schuit E, Panagiotou OA, Munafò MR, Bennett DA, Bergen AW, David SP. Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers. Cochrane Database Syst Rev. 2017;9:CD011823.
pubmed: 28884473
Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2013;2013:CD009329.
pubmed: 23728690
pmcid: 8406789
Hartmann-Boyce J, Stead LF, Cahill K, Lancaster T. Efficacy of interventions to combat tobacco addiction: cochrane update of 2013 reviews. Addiction. 2014;109:1414–25.
pubmed: 24995905
doi: 10.1111/add.12633
Jordan CJ, Xi Z-X. Discovery and development of varenicline for smoking cessation. Expert Opin Drug Discov. 2018;0:1–12.
Niaura R, Hays JT, Jorenby DE, Leone FT, Pappas JE, Reeves KR, et al. The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial. Curr Med Res Opin. 2008;24:1931–41.
pubmed: 18513462
doi: 10.1185/03007990802177523
Oncken C, Gonzales D, Nides M, Rennard S, Watsky E, Billing CB, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med. 2006;166:1571–7.
pubmed: 16908789
doi: 10.1001/archinte.166.15.1571
Kranzler HR, Smith RV, Schnoll R, Moustafa A, Greenstreet-Akman E. Precision medicine and pharmacogenetics: what does oncology have that addiction medicine does not? Addiction. 2017;112:2086–94.
pubmed: 28431457
pmcid: 5650957
doi: 10.1111/add.13818
Lerman C, LeSage MG, Perkins KA, O’Malley SS, Siegel SJ, Benowitz NL, et al. Translational research in medication development for nicotine dependence. Nat Rev Drug Discov. 2007;6:746–62.
pubmed: 17690709
doi: 10.1038/nrd2361
O’Dell LE, Khroyan TV. Rodent models of nicotine reward: What do they tell us about tobacco abuse in humans? Pharmacol Biochem Behav. 2009;91:481–8.
pubmed: 19121334
doi: 10.1016/j.pbb.2008.12.011
Le Foll B, Pushparaj A, Pryslawsky Y, Forget B, Vemuri K, Makriyannis A, et al. Translational strategies for therapeutic development in nicotine addiction: Rethinking the conventional bench to bedside approach. Prog Neuro-Psychopharmacol Biol Psychiatry. 2014;52:86–93.
doi: 10.1016/j.pnpbp.2013.10.009
Field M, Kersbergen I. Are animal models of addiction useful? Addiction. 2020;115:6–12.
pubmed: 31353760
doi: 10.1111/add.14764
Rose JE, Corrigall WA. Nicotine self-administration in animals and humans: similarities and differences. Psychopharmacology (Berl). 1997;130:28–40.
pubmed: 9089846
doi: 10.1007/s002130050209
Donny EC, Chaudhri N, Caggiula AR, Evans-Martin FF, Booth S, Gharib MA, et al. Operant responding for a visual reinforcer in rats is enhanced by noncontingent nicotine: implications for nicotine self-administration and reinforcement. Psychopharmacology (Berl). 2003;169:68–76.
pubmed: 12774186
doi: 10.1007/s00213-003-1473-3
Deroche-Gamonet V, Piat F, Le Moal M, Piazza PV. Influence of cue-conditioning on acquisition, maintenance and relapse of cocaine intravenous self-administration. Eur J Neurosci. 2002;15:1363–70.
pubmed: 11994130
doi: 10.1046/j.1460-9568.2002.01974.x
Garcia-Rivas V, Fiancette J-F, Cannella N, Carbo-Gas M, Renault P, Tostain J, et al. Varenicline targets the reinforcing-enhancing effect of nicotine on its associated salient cue during nicotine self-administration in the rat. Front Behav Neurosci. 2019;13:159.
pubmed: 31379531
pmcid: 6650579
doi: 10.3389/fnbeh.2019.00159
Olsen CM, Winder DG. Operant sensation seeking engages similar neural substrates to operant drug seeking in C57 mice. Neuropsychopharmacol. 2009;34:1685–94.
doi: 10.1038/npp.2008.226
Contet C, Whisler KN, Jarrell H, Kenny PJ, Markou A. Patterns of responding differentiate intravenous nicotine self-administration from responding for a visual stimulus in C57BL/6J mice. Psychopharmacology. 2010;212:283–99.
pubmed: 20668842
pmcid: 2952765
doi: 10.1007/s00213-010-1950-4
Faul F, Erdfelder E, Lang A-G, Buchner AG. *Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39:175–91.
Donny EC, Caggiula AR, Knopf S, Brown C. Nicotine self-administration in rats. Psychopharmacology. 1995;122:390–4.
pubmed: 8657839
doi: 10.1007/BF02246272
Pushparaj A, Pryslawsky Y, Forget B, Yan Y, Foll BL. Extinction bursts in rats trained to self-administer nicotine or food in 1-h daily sessions. Am J Transl Res. 2012;4:422–31.
pubmed: 23145210
pmcid: 3493025
Olfson E, Bloom J, Bertelsen S, Budde JP, Breslau N, Brooks A, et al. CYP2A6 metabolism in the development of smoking behaviors in young adults. Addict Biol. 2018;23:437–47.
Grebenstein PE, Burroughs D, Roiko SA, Pentel PR, LeSage MG. Predictors of the nicotine reinforcement threshold, compensation, and elasticity of demand in a rodent model of nicotine reduction policy. Drug Alcohol Depend. 2015;151:181–93.
pubmed: 25891231
pmcid: 4447604
doi: 10.1016/j.drugalcdep.2015.03.030
Formann AK. Die Latent-Class-Analyse: Einführung in Theorie und Anwendung. Weinheim [W. Germany]: Beltz; 1984.
Cohen C, Perrault G, Griebel G, Soubrié P. Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716). Neuropsychopharmacology. 2005;30:145–55.
pubmed: 15292905
doi: 10.1038/sj.npp.1300541
Constantin A, Clarke PBS. Reinforcement enhancement by nicotine in adult rats: behavioral selectivity and relation to mode of delivery and blood nicotine levels. Psychopharmacology. 2018;235:641–50.
Cohen A, George O. Animal models of nicotine exposure: relevance to second-hand smoking, electronic cigarette use, and compulsive smoking. Front Psychiatry. 2013;4:41.
pubmed: 23761766
pmcid: 3671664
doi: 10.3389/fpsyt.2013.00041
Garcia-Rivas V, Cannella N, Deroche-Gamonet V. Individual variations in the mechanisms of nicotine seeking: a key for research on nicotine dependence. Neuropsychopharmacology. 2017;42:584–86.
pubmed: 27577600
doi: 10.1038/npp.2016.176
Newby PK, Tucker KL. Empirically derived eating patterns using factor or cluster analysis: a review. Nutr Rev. 2004;62:177–203.
pubmed: 15212319
doi: 10.1111/j.1753-4887.2004.tb00040.x
Clemens KJ, Lay BPP, Holmes NM. Extended nicotine self-administration increases sensitivity to nicotine, motivation to seek nicotine and the reinforcing properties of nicotine-paired cues. Addict Biol. 2017;22:400–10.
pubmed: 26626055
doi: 10.1111/adb.12336
Grimm JW, Ratliff C, North K, Barnes J, Collins S. Nicotine increases sucrose self-administration and seeking in rats. Addict Biol. 2012;17:623–33.
pubmed: 22340200
pmcid: 3331958
doi: 10.1111/j.1369-1600.2012.00436.x
Rupprecht LE, Smith TT, Schassburger RL, Buffalari DM, Sved AF, Donny EC. Behavioral mechanisms underlying nicotine reinforcement. Curr Top Behav Neurosci. 2015;24:19–53.
pubmed: 25638333
pmcid: 4536896
doi: 10.1007/978-3-319-13482-6_2
Perkins KA, Karelitz JL, Boldry MC. Nicotine acutely enhances reinforcement from non-drug rewards in humans. Front Psychiatry. 2017;8:65.
pubmed: 28507522
pmcid: 5410601
doi: 10.3389/fpsyt.2017.00065
Palmatier MI, Matteson GL, Black JJ, Liu X, Caggiula AR, Craven L, et al. The reinforcement enhancing effects of nicotine depend on the incentive value of non-drug reinforcers and increase with repeated drug injections. Drug Alcohol Depend. 2007;89:52–9.
pubmed: 17240084
pmcid: 1955684
doi: 10.1016/j.drugalcdep.2006.11.020
Levin ME, Weaver MT, Palmatier MI, Caggiula AR, Sved AF, Donny EC. Varenicline dose dependently enhances responding for nonpharmacological reinforcers and attenuates the reinforcement-enhancing effects of nicotine. Nicotine Tob Res. 2012;14:299–305.
pubmed: 21994342
doi: 10.1093/ntr/ntr213
Perkins KA, Karelitz JL, Michael VC. Reinforcement enhancing effects of acute nicotine via electronic cigarettes. Drug Alcohol Depend. 2015;153:104–8.
pubmed: 26070455
pmcid: 4509912
doi: 10.1016/j.drugalcdep.2015.05.041
Liu X, Palmatier MI, Caggiula AR, Donny EC, Sved AF. Reinforcement enhancing effect of nicotine and its attenuation by nicotinic antagonists in rats. Psychopharmacology (Berl). 2007;194:463–73.
pubmed: 17616849
doi: 10.1007/s00213-007-0863-3
Perkins KA, Karelitz JL. Influence of reinforcer magnitude and nicotine amount on smoking’s acute reinforcement enhancing effects. Drug Alcohol Depend. 2013;133:167–71.
pubmed: 23768842
pmcid: 3786025
doi: 10.1016/j.drugalcdep.2013.05.016
Perkins KA, Karelitz JL. Sensory reinforcement-enhancing effects of nicotine via smoking. Exp Clin Psychopharmacol. 2014;22:511–6.
pubmed: 25180451
pmcid: 4250279
doi: 10.1037/a0037823
Martin LM, Sayette MA. A review of the effects of nicotine on social functioning. Exp Clin Psychopharmacol. 2018;26:425–39.
pubmed: 29952615
pmcid: 6162172
doi: 10.1037/pha0000208
Perkins KA, Karelitz JL, Boldry MC. Reinforcement enhancing effects of nicotine via patch and nasal spray. Nicotine Tob Res. 2019;21:778–83.
pubmed: 29514317
doi: 10.1093/ntr/nty038
Satanove DJ, Rahman S, Chan TMV, Ren S, Clarke PBS. Nicotine-induced enhancement of a sensory reinforcer in adult rats: antagonist pretreatment effects. Psychopharmacology (Berl). 2021;238:475–86.
pubmed: 33150479
doi: 10.1007/s00213-020-05696-5
Pergadia ML, Der-Avakian A, D’Souza MS, Madden PAF, Heath AC, Shiffman S, et al. Association between nicotine withdrawal and reward responsiveness in humans and rats. JAMA Psychiatry. 2014;71:1238–45.
pubmed: 25208057
pmcid: 4353576
doi: 10.1001/jamapsychiatry.2014.1016
Cook JW, Piper ME, Leventhal AM, Schlam TR, Fiore MC, Baker TB. Anhedonia as a component of the tobacco withdrawal syndrome. J Abnorm Psychol. 2015;124:215–25.
pubmed: 25384069
doi: 10.1037/abn0000016
Piper ME. Withdrawal: expanding a key addiction construct. Nicotine Tob Res. 2015;17:1405–15.
pubmed: 25744958
pmcid: 4654762
doi: 10.1093/ntr/ntv048
Piper ME, Vasilenko SA, Cook JW, Lanza ST. What a difference a day makes: differences in initial abstinence response during a smoking cessation attempt. Addiction. 2017;112:330–9.
pubmed: 27633341
doi: 10.1111/add.13613
Perkins KA. Acute responses to nicotine and smoking: implications for prevention and treatment of smoking in lower SES women. Drug Alcohol Depend. 2009;104:S79–86.
pubmed: 19084357
doi: 10.1016/j.drugalcdep.2008.10.022
Audrain-McGovern J, Wileyto EP, Ashare R, Cuevas J, Strasser AA. Reward and affective regulation in depression-prone smokers. Biol Psychiatry. 2014;76:689–97.
pubmed: 24947541
pmcid: 4186900
doi: 10.1016/j.biopsych.2014.04.018
Leventhal AM. The sociopharmacology of tobacco addiction: implications for understanding health disparities. Nicotine Tob Res. 2016;18:110–21.
pubmed: 25890832
doi: 10.1093/ntr/ntv084
Lee JO, Cho J, Yoon Y, Bello MS, Khoddam R, Leventhal AM. Developmental pathways from parental socioeconomic status to adolescent substance use: alternative and complementary reinforcement. J Youth Adolesc. 2018;47:334–48.
pubmed: 29188410
doi: 10.1007/s10964-017-0790-5
Johnson MW, Bickel WK, Kirshenbaum AP. Substitutes for tobacco smoking: a behavioral economic analysis of nicotine gum, denicotinized cigarettes, and nicotine-containing cigarettes. Drug Alcohol Depend. 2004;74:253–64.
pubmed: 15194203
doi: 10.1016/j.drugalcdep.2003.12.012
Donny EC, Jones M. Prolonged exposure to denicotinized cigarettes with or without transdermal nicotine. Drug Alcohol Depend. 2009;104:23–33.
pubmed: 19446968
pmcid: 2726800
doi: 10.1016/j.drugalcdep.2009.01.021
Shram MJ, Funk D, Li Z, Lê AD. Nicotine self-administration, extinction responding and reinstatement in adolescent and adult male rats: evidence against a biological vulnerability to nicotine addiction during adolescence. Neuropsychopharmacol. 2008;33:739–48.
doi: 10.1038/sj.npp.1301454
Tiffany ST, Hakenewerth DM. The production of smoking urges through an imagery manipulation: psychophysiological and verbal manifestations. Addict Behav. 1991;16:389–400.
pubmed: 1801563
doi: 10.1016/0306-4603(91)90047-L
Cepeda-Benito A, Tiffany ST. The use of a dual-task procedure for the assessment of cognitive effort associated with cigarette craving. Psychopharmacology (Berl). 1996;127:155–63.
pubmed: 8888382
doi: 10.1007/BF02805989
Tiffany ST, Cox LS, Elash CA. Effects of transdermal nicotine patches on abstinence-induced and cue-elicited craving in cigarette smokers. J Consult Clin Psychol. 2000;68:233–40.
pubmed: 10780123
doi: 10.1037/0022-006X.68.2.233
Dallery J, Houtsmuller EJ, Pickworth WB, Stitzer ML. Effects of cigarette nicotine content and smoking pace on subsequent craving and smoking. Psychopharmacology (Berl). 2003;165:172–80.
pubmed: 12417964
doi: 10.1007/s00213-002-1242-8
Barrett SP. The effects of nicotine, denicotinized tobacco, and nicotine-containing tobacco on cigarette craving, withdrawal, and self-administration in male and female smokers. Behav Pharm. 2010;21:144–52.
doi: 10.1097/FBP.0b013e328337be68
Baker TB, Japuntich SJ, Hogle JM, McCarthy DE, Curtin JJ. Pharmacologic and behavioral withdrawal from addictive drugs. Curr Dir Psychol Sci. 2006;15:232–6.
doi: 10.1111/j.1467-8721.2006.00442.x
Rose JE, Herskovic JE, Trilling Y, Jarvik ME. Transdermal nicotine reduces cigarette craving and nicotine preference. Clin Pharm Ther. 1985;38:450–6.
doi: 10.1038/clpt.1985.203
Brauer LH, Behm FM, Lane JD, Westman EC, Perkins C, Rose JE. Individual differences in smoking reward from de-nicotinized cigarettes. Nicotine Tob Res. 2001;3:101–9.
pubmed: 11403723
doi: 10.1080/14622200123249
Niaura R, Abrams DB, Pedraza M, Monti PM, Rohsenow DJ. Smokers’ reactions to interpersonal interaction and presentation of smoking cues. Addict Behav. 1992;17:557–66.
pubmed: 1488936
doi: 10.1016/0306-4603(92)90065-4
Conklin CA, Tiffany ST. The impact of imagining personalized versus standardized urge scenarios on cigarette craving and autonomic reactivity. Exp Clin Psychopharmacol. 2001;9:399–408.
pubmed: 11764016
doi: 10.1037/1064-1297.9.4.399
Van Gucht D, Van den Bergh O, Beckers T, Vansteenwegen D. Smoking behavior in context: where and when do people smoke? J Behav Ther Exp Psychiatry. 2010;41:172–7.
pubmed: 20060515
doi: 10.1016/j.jbtep.2009.12.004
Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem. 2005;48:3474–7.
pubmed: 15887955
doi: 10.1021/jm050069n
Rollema H, Coe JW, Chambers LK, Hurst RS, Stahl SM, Williams KE. Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation. Trends Pharm Sci. 2007;28:316–25.
pubmed: 17573127
doi: 10.1016/j.tips.2007.05.003
Rollema H, Chambers LK, Coe JW, Glowa J, Hurst RS, Lebel LA, et al. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology. 2007;52:985–94.
pubmed: 17157884
doi: 10.1016/j.neuropharm.2006.10.016
Ebbert JO, Wyatt KD, Hays JT, Klee EW, Hurt RD. Varenicline for smoking cessation: efficacy, safety, and treatment recommendations. Patient Prefer Adherence. 2010;4:355–62.
pubmed: 21049087
pmcid: 2962400
doi: 10.2147/PPA.S10620
Falco AM, Bevins RA. Individual differences in the behavioral effects of nicotine: a review of the preclinical animal literature. Pharm Biochem Behav. 2015;138:80–90.
doi: 10.1016/j.pbb.2015.09.017
Yager LM, Robinson TE. Individual variation in the motivational properties of a nicotine cue: sign-trackers vs. goal-trackers. Psychopharmacology (Berl). 2015;232:3149–60.
pubmed: 25980485
doi: 10.1007/s00213-015-3962-6
Allenby CE, Boylan KA, Lerman C, Falcone M. Precision medicine for tobacco dependence: development and validation of the nicotine metabolite ratio. J Neuroimmune Pharmacol. 2016;11:471–83.
Kazan T, Charntikov S. Individual differences in responding to bupropion or varenicline in a preclinical model of nicotine self-administration vary according to individual demand for nicotine. Neuropharmacology. 2019;148:139–50.
pubmed: 30611697
pmcid: 6457454
doi: 10.1016/j.neuropharm.2018.12.031
Sved AF, Caggiula AR, Donny EC. Elucidating the reinforcing effects of nicotine: a tribute to Nadia Chaudhri. Psychopharmacology (Berl). 2023;240:417–30.
pubmed: 36329195
doi: 10.1007/s00213-022-06266-7
Chenoweth MJ, Tyndale RF. Pharmacogenetic optimization of smoking cessation treatment. Trends Pharmacol Sci. 2017;38:55–66.
pubmed: 27712845
doi: 10.1016/j.tips.2016.09.006
Chen L-S, Horton A, Bierut L. Pathways to precision medicine in smoking cessation treatments. Neurosci Lett. 2018;669:83–92.
pubmed: 27208830
doi: 10.1016/j.neulet.2016.05.033
Siegel SD, Tindle HA, Bergen AW, Tyndale RF, Schnoll R. The use of biomarkers to guide precision treatment for tobacco use. Addict Neurosci. 2023;6:100076.
pubmed: 37089247
pmcid: 10121195
doi: 10.1016/j.addicn.2023.100076
Bierut LJ. 2018 Langley award for basic research on nicotine and tobacco: bringing precision medicine to smoking cessation. Nicotine Tob Res. 2020;22:147–51.
pubmed: 30855677
doi: 10.1093/ntr/ntz036
Chen L-S, Baker TB, Ramsey A, Amos CI, Bierut LJ. Genomic medicine to reduce tobacco and related disorders: translation to precision prevention and treatment. Addict Neurosci. 2023;7:100083.
pubmed: 37602286
pmcid: 10434839
doi: 10.1016/j.addicn.2023.100083
Ahrens S, Markett S, Breckel TPK, Behler O, Reuter M, Thiel CM. Modulation of nicotine effects on selective attention by DRD2 and CHRNA4 gene polymorphisms. Psychopharmacology (Berl). 2015;232:2323–31.
pubmed: 25647695
doi: 10.1007/s00213-015-3869-2
Bauman KE, Foshee VA, Haley NJ. The interaction of sociological and biological factors in adolescent cigarette smoking. Addict Behav. 1992;17:459–67.
pubmed: 1442239
doi: 10.1016/0306-4603(92)90006-H
Jamner LD, Whalen CK, Loughlin SE, Mermelstein R, Audrain-McGovern J, Krishnan-Sarin S, et al. Tobacco use across the formative years: a road map to developmental vulnerabilities. Nicotine Tob Res. 2003;5:S71–87.
pubmed: 14668088
doi: 10.1080/14622200310001625573
Cummings KM, Fong GT, Borland R. Environmental influences on tobacco use: evidence from societal and community influences on tobacco use and dependence. Annu Rev Clin Psychol. 2009;5:433–58.
pubmed: 19327036
doi: 10.1146/annurev.clinpsy.032408.153607
Verplaetse TL, Morris ED, McKee SA, Cosgrove KP. Sex differences in the nicotinic acetylcholine and dopamine receptor systems underlying tobacco smoking addiction. Curr Opin Behav Sci. 2018;23:196–202.
pubmed: 31341936
pmcid: 6656369
doi: 10.1016/j.cobeha.2018.04.004